Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) PT at $1.93

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $1.93.

Separately, D. Boral Capital reduced their price target on Carisma Therapeutics from $12.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st.

Hedge Funds Weigh In On Carisma Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Carisma Therapeutics in the 1st quarter worth approximately $62,000. Finally, Renaissance Technologies LLC grew its stake in shares of Carisma Therapeutics by 11.9% in the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after buying an additional 24,600 shares during the last quarter. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Stock Down 7.5%

CARM stock opened at $0.18 on Friday. Carisma Therapeutics has a twelve month low of $0.16 and a twelve month high of $1.90. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock’s 50 day moving average is $0.26 and its 200-day moving average is $0.48. The firm has a market capitalization of $7.45 million, a PE ratio of -0.11 and a beta of 1.79.

Carisma Therapeutics (NASDAQ:CARM) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The company had revenue of $3.65 million for the quarter, compared to the consensus estimate of $2.47 million. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Sell-side analysts expect that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.